Gordian Capital Singapore Pte Ltd Decreases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Gordian Capital Singapore Pte Ltd lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 50.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,498 shares of the company’s stock after selling 3,602 shares during the quarter. Gordian Capital Singapore Pte Ltd’s holdings in Novo Nordisk A/S were worth $417,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Natixis Advisors LLC increased its position in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the last quarter. Zions Bancorporation N.A. increased its position in shares of Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Novo Nordisk A/S by 14.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after purchasing an additional 37,346 shares during the last quarter. Private Wealth Partners LLC increased its position in shares of Novo Nordisk A/S by 155.1% during the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock valued at $3,953,000 after purchasing an additional 20,188 shares during the last quarter. Finally, MayTech Global Investments LLC increased its position in shares of Novo Nordisk A/S by 14.1% during the 3rd quarter. MayTech Global Investments LLC now owns 254,552 shares of the company’s stock valued at $30,309,000 after purchasing an additional 31,475 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.8 %

Shares of NYSE:NVO opened at $110.77 on Monday. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The stock has a market cap of $497.08 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 1.41 and a beta of 0.40. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $111.31 and a 200-day moving average price of $127.07.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, BMO Capital Markets cut their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $150.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.